Evidence map›Paper›PMID 33841637›Full record

ArticleAmerican journal of translational research2021

LncRNA RUSC1-AS1 contributes to the progression of hepatocellular carcinoma cells by modulating miR-340-5p/CREB1 axis.

Chunjiang Liu, Liming Tang, Miaojun Xu, Yuting Lin, Jingfu Shen, Liang Zhou, Lichen Ho, Jinjing Lu, Xiaoming Ai

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. World journal of gastroenterology · 2025
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Chunjiang LiuDepartment of General Surgery, Shaoxing People's Hospital (Shaoxing Hospital of Zhejiang University) Shaoxing, Zhejiang, China.
Liming TangDepartment of General Surgery, Shaoxing People's Hospital (Shaoxing Hospital of Zhejiang University) Shaoxing, Zhejiang, China.
Miaojun XuDepartment of General Surgery, Shaoxing People's Hospital (Shaoxing Hospital of Zhejiang University) Shaoxing, Zhejiang, China.
Yuting LinDepartment of General Surgery, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University Nanjing, Jiangsu, China.
Jingfu ShenDepartment of General Surgery, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University Nanjing, Jiangsu, China.
Liang ZhouDepartment of General Surgery, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University Nanjing, Jiangsu, China.
Lichen HoDepartment of General Surgery, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University Nanjing, Jiangsu, China.
Jinjing LuDepartment of General Surgery, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University Nanjing, Jiangsu, China.
Xiaoming AiDepartment of General Surgery, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University Nanjing, Jiangsu, China.
Nanjing Medical University · CNShaoxing People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent studies have proven that there is a relationship between long non-coding RNAs (lncRNAs) and malignant tumor hepatocellular carcinoma (HCC). However, the function of RUSC1-AS1 and its relative regulators in HCC remains unknown.

methods

resultsWhen compared with normal groups, RUSC1-AS1 expression in HCC tissues and HCC cell lines was higher. We also found that knockdown of RUSC1-AS1 inhibited HCC cell progression, including proliferation, migration, and invasion, and suppressed tumorigenesis

conclusionWe demonstrated that lncRNA RUSC1-AS1 influenced HCC cell progression by modulating its downstream target miR-340-5p/CREB1 axis via the PI3K/AKT signaling pathway, which may be a potential prognostic and therapeutic target for treating HCC.

Indexed as

CREB1hepatocellular carcinomainvasionLncRNA RUSC1-AS1miR-340-5p

Identifiers

PMID33841637
PMCPMC8014390
OpenAlexW3154307153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.